IDEXX Laboratories, Inc.’s stock price stumbles, closing at $474.94 with a 2.64% drop

IDEXX Laboratories, Inc. (IDXX)

474.94 USD -12.88 (-2.64%) Volume: 0.54M

Discover IDEXX Laboratories, Inc.’s stock price performance, currently trading at 474.94 USD, experiencing a downturn of -2.64% this session with a trading volume of 0.54M. Despite a YTD percentage change of -14.43%, the company remains a significant player in the market.

Latest developments on IDEXX Laboratories, Inc.

Despite facing headwinds from low U.S. clinical visits in Q2, IDEXX Laboratories Inc. (NASDAQ:IDXX) saw its stock rise on Tuesday, although it still underperformed the market. The company’s stock price was affected by Piper Sandler cutting its price target to $520.00. However, Sequoia Financial Advisors LLC purchased shares of IDEXX Laboratories, Inc., while QRG Capital Management Inc. sold some of their shares. Czech National Bank also increased its stock holdings in IDEXX Laboratories, Inc. to $7.67 million. These various movements in stock ownership and price targets have contributed to the fluctuations in IDEXX Laboratories‘ stock price today.

IDEXX Laboratories, Inc. on Smartkarma

Analysts at Baptista Research on Smartkarma have provided positive coverage of IDEXX Laboratories, highlighting the company’s strong performance in 2023 and 2024. In their report titled “IDEXX Laboratories: Fusion Of Innovation & Service Excellence In Veterinary Diagnostics! – Major Drivers,” the analysts noted that IDEXX began 2024 on a positive note with strong profit gains and solid organic revenue growth. Despite adverse effects from severe U.S. weather in January, the company still saw a 7% organic growth in Companion Animal Group (CAG) Diagnostic recurring revenues. This growth was a key driver for the company’s overall revenue increase.

Furthermore, in their report “IDEXX Laboratories: Growing Global Direct Commercial Capability & Other Major Drivers,” Baptista Research highlighted IDEXX’s strong quarterly and annual results in 2023. The company reported an 8% organic revenue increase in Q4, driven by gains in CAG Diagnostic recurring revenues. Operating profits also rose 8% with a 10% increase on a comparable basis, supported by gross margin gains and operational expense leverage. Overall, the analysts’ sentiment on IDEXX Laboratories remains bullish based on their analysis of the company’s financial performance and growth prospects.

A look at IDEXX Laboratories, Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Looking at the Smartkarma Smart Scores for IDEXX Laboratories, the company appears to have a promising long-term outlook. With a strong momentum score of 4, IDEXX Laboratories seems to be on a positive trajectory for growth and success in the future. Additionally, the company’s growth score of 3 suggests that it is well-positioned to expand and increase its market presence in the coming years. While the value and resilience scores are not as high, IDEXX Laboratories‘ overall outlook seems to be positive based on the Smart Scores.

As a provider of diagnostic, detection, and information systems for various testing applications, including veterinary, food, and water testing, IDEXX Laboratories has a diverse range of products and services to offer. With an international network of veterinary reference laboratories, the company serves customers globally, indicating a strong market presence. Despite some lower scores in certain areas, IDEXX Laboratories‘ overall outlook appears to be optimistic, especially considering its momentum and growth scores.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma